⠀
• Moderna and Merck report Phase 3 success for Intismeran + KEYTRUDA in melanoma. Both the primary endpoint, recurrence-free survival, and the key secondary endpoint, distant metastasis-free survival, were met. $MRNA is currently up about +90% in premarket trading.
• The implications could extend far beyond melanoma: The study provides important Phase 3 validation for the concept of personalized mRNA cancer vaccines. Intismeran is already being investigated for several other tumor types.
• Potential spillover effects / peers:
$MRK +8.5% — Moderna’s direct 50/50 partner on Intismeran.
$BNTX +16% — Developing its own personalized mRNA cancer vaccine platform with Roche/Genentech.
$MRVI +19.5% — mRNA “picks and shovels” via TriLink, CleanCap, and manufacturing technologies.
$ARCT +18.8% — An mRNA platform company that could benefit from broader validation of the technology.
$HURA +7.4% — Cancer vaccine exposure, including mRNA-related technologies.
$EVAX -5% — Special case: develops personalized neoantigen cancer vaccines, though peptide-based rather than mRNA-based. The stock initially rose by about +35% before the move was completely sold off.